The human microbiome plays a significant role in regulating immune function, inflammation, and disease progression, making it an increasingly important area of study in oncology. Research has linked microbial composition and diversity to treatment responses and complications in patients with cancer undergoing immunotherapies and hematopoietic cell transplantation (HCT).
In this webinar, Robert Jenq will discuss current research exploring the relationship between the microbiome and cancer development, as well as its impact on treatment outcomes in allogeneic HCT, graft-versus-host disease (GVHD), immune checkpoint inhibitor therapy, and CAR T cell therapy.
Topics to be covered:
- The relationship between the microbiome and cancer development
- How microbial diversity may influence immune responses during cancer treatment
- The role of the microbiome in allogeneic HCT outcomes
- Current research into GVHD and microbial interactions
Wednesday, July 15th 2026 | 11:00 AM – 12:00 PM Eastern Time
This webinar will be available to view live and on demand.
Speaker
.png "Robert Jenq, MD")
Robert Jenq, MD
Professor
Department of Hematology and HCT
City of Hope